Safety Of Remission Induction With Rituximab Versus Cyclosphosphamide In Patients 65 and Older With Severe ANCA-Associated Vasculitis

被引：0

作者：

Miloslavsky, Eli ^{[1
]}

Specks, Ulrich ^{[2
]}

Merkel, Peter A. ^{[3
,4
]}

Seo, Philip ^{[5
]}

Spiera, Robert F. ^{[6
]}

Langford, Carol A. ^{[7
]}

Hoffman, Gary S. ^{[8
]}

Kallenberg, Cees G. M. ^{[9
]}

St Clair, E. William ^{[10
]}

Tchao, Nadia ^{[11
]}

Ding, Linna ^{[12
]}

Ikle, David ^{[13
]}

Jepson, Brett ^{[13
]}

Brunetta, Paul ^{[14
]}

Stone, John H. ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Mayo Clin, Rochester, MN USA

[3] Univ Penn, Philadelphia, PA 19104 USA

[4] VA Med Ctr, Philadelphia, PA USA

[5] Johns Hopkins Vasculitis Ctr, Baltimore, MD USA

[6] Hosp Special Surg, New York, NY 10021 USA

[7] Cleveland Clin, Cleveland, OH 44106 USA

[8] Cleveland Clin Fdn, Cleveland, OH 44195 USA

[9] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands

[10] Duke Univ, Med Ctr, Durham, NC USA

[11] Immune Tolerance Network, Bethesda, MD USA

[12] NIAID, Bethesda, MD 20892 USA

[13] Rho, Chapel Hill, NC USA

[14] Genentech Inc, So San Francisco, CA USA

来源：

ARTHRITIS AND RHEUMATISM | 2013年 / 65卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

742

引用

页码：S313 / S313

页数：1

共 50 条

[1] Safety of remission induction with rituximab versus cyclophosphamide in patients 65 and older with severe ANCA-associated vasculitis
Miloslavsky, E.
Specks, U.
Merkel, P.
Seo, P.
Spiera, R.
Langford, C.
Hoffman, G.
Kallenberg, C.
St Clair, W.
Tchao, N.
Ding, L.
Ikle, D.
Jepson, B.
Brunetta, P.
Stone, J.
PRESSE MEDICALE, 2013, 42 (04): : 779 - 780
[2] Rituximab for remission induction in elderly patients with ANCA-associated vasculitis
Timlin, H.
Lee, S. M.
Manno, R. L.
Seo, P.
Geetha, Duvura
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2015, 45 (01) : 67 - 69
[3] DETERMINANTS OF RITUXIMAB PHARMACOKINETICS AND REMISSION INDUCTION IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS
Cornec, Divi
Kabat, Brian F.
Mills, John R.
Cheu, Melissa
Hummel, Amber M.
Schroeder, Darrell R.
Cascino, Matthew D.
Brunetta, Paul
Murray, David L.
Snyder, Melissa R.
Fervenza, Fernando
Hoffman, Gary S.
Kallenberg, Cees G. M.
Langford, Carol A.
Merkel, Peter A.
Monach, Paul A.
Seo, Philip
Spiera, Robert F.
Clair, E. William St.
Stone, John H.
Barnidge, David R.
Specks, Ulrich
RHEUMATOLOGY, 2017, 56 : 154 - 154
[4] Is Rituximab Superior to Cyclophosphamide for ANCA-Associated Vasculitis for Induction of Remission, and with a Better Safety Profile?
Ignacio Garcia-Valladares
Luis R. Espinoza
Current Rheumatology Reports, 2010, 12 (6) : 395 - 398
[5] Remission induction in ANCA-associated vasculitis
Hellmich, B.
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2014, 73 (02): : 194 - 195
[6] Rituximab remission strategies in ANCA-associated vasculitis
Thorley, Jennifer
LANCET RHEUMATOLOGY, 2024, 6 (02): : E71 - E71
[7] A RANDOMIZED, CONTROLLED TRIAL OF RITUXIMAB VERSUS AZATHIOPRINE AFTER INDUCTION OF REMISSION WITH RITUXIMAB FOR PATIENTS WITH ANCA-ASSOCIATED VASCULITIS AND RELAPSING DISEASE
Smith, R.
Jayne, D.
Merkel, P. A.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 19 - 20
[8] A RANDOMIZED, CONTROLLED TRIAL OF RITUXIMAB VERSUS AZATHIOPRINE AFTER INDUCTION OF REMISSION WITH RITUXIMAB FOR PATIENTS WITH ANCA-ASSOCIATED VASCULITIS AND RELAPSING DISEASE
Smith, Rona
Jayne, David
Merkel, Peter
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 2185 - 2185
[9] A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease
Smith, Rona
Jayne, David
Merkel, Peter
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[10] Safety and Efficacy of Avacopan in Patients 65 Years and Older with ANCA-Associated Vasculitis
Rauen, Thomas
Geetha, Duvuru
Pagnoux, Christian
Sattui, Sebastian E.
Merkel, Peter A.
Jayne, David R.
INNERE MEDIZIN, 2024, 65 : S87 - S88

← 1 2 3 4 5 →